Results 101 to 110 of about 7,834 (208)

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Targeted Therapies for Each Subtype of Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review systematically summarizes the advances in targeted therapies for the three major molecular subtypes of breast cancer (BC), highlighting key strategies, agents, and clinical progress to guide personalized treatment. HR‐positive (luminal) BC: Dominated by estrogen receptor (ER) signaling, with endocrine therapies as the cornerstone—including ...
Aiyu Liu, Puchao Peng, Yeke Zhu, Qiuwen Fei, Weiwei Liu, Shizhen Zhang   +5 more
wiley   +1 more source

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

Frontiers in Oncology, 2019
The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma.
Paige Baldwin, Rostislav Likhotvorik, Nabeela Baig, Jodie Cropper, Ruth Carlson, Raushan Kurmasheva, Raushan Kurmasheva, Srinivas Sridhar, Srinivas Sridhar, Srinivas Sridhar   +9 more
doaj   +1 more source

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

Drugs in R&D, 2020
Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and ...
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis   +8 more
doaj   +1 more source

Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. [PDF]

, 2019
Accessory male breast cancer (BC) is a rare entity and is associated with poor outcome. We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation ...
Cheng, Yu, Eapen, Ann, Li, Ningjing, Mehta, Rita, Parajuli, Ritesh   +4 more
core  

Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High‐Risk Metastatic Hormone‐Naïve Prostate Cancer: Results From a 3‐Year Interim Analysis of the J‐ROCK Study

The Prostate, Volume 86, Issue 5, Page 599-608, April 2026.
ABSTRACT Introduction In real‐world practice in Japan, standard treatment for metastatic hormone‐naïve prostate cancer (mHNPC) is androgen deprivation therapy (ADT), administered as monotherapy, combined androgen blockade (CAB), ADT plus androgen receptor pathway inhibitors (ARPIs), or ADT plus docetaxel.
Atsushi Mizokami, Rikiya Matsumoto, Hideaki Miyake, Hiroji Uemura, Hirotsugu Uemura, Satoru Kawakami, Kazuyoshi Nakamura, Shigekatsu Maekawa, Hiroaki Tsuchiya, Sachie Okazaki, Eri Adachi, Ryo Yano, Yohei Tajima, Kiyohide Fujimoto, Hideyasu Matsuyama   +14 more
wiley   +1 more source

Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparib

, 2023
Abstract Cancers often have reduced allelic diversity because of loss of heterozygosity (LOH). Therefore, tumors arising in patients heterozygous for a functional and a loss-of-functon(LoF) allele may lose the functional allele, rendering them sensitive to allele-specific therapies.
Tobias Sjöblom, Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Al Azhar, Ioanna Tsiara, Pauline Seeburger, Shahed Al Nassralla, Viktor Ljungström, Richard Svensson, Ivaylo Stoimenov, Per Artursson, Markus Heim, Daniel Globisch   +17 more
openaire   +2 more sources

Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells [PDF]

, 2019
Therapeutic targeting of estrogen receptor-α (ERα) by the anti-estrogen tamoxifen is standard of care for premenopausal breast cancer patients and remains a key component of treatment strategies for postmenopausal patients.
Clarke, Robert, Fang, Fang, Miller, Kathy D., Nephew, Kenneth P., O'Hagan, Heather M., Pulliam, Nicholas, Sood, Riddhi, Tang, Jessica, Wang, Weini   +8 more
core   +1 more source

Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers

Advanced Science
Synthetic lethality in homologous recombination (HR)‐deficient cancers caused by Poly (ADP‐ribose) polymerase inhibitors (PARPi) has been classically attributed to its role in DNA repair.
Ganesh Pai Bellare, Kshama Kundu, Papiya Dey, Krupa Thankam Philip, Nitish Chauhan, Muskan Sharma, Sankarsingh Kesharsingh Rajput, Birija Sankar Patro   +7 more
doaj   +1 more source

Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis [PDF]

, 2017
The cell-surface glycoprotein CD56 has three major isoforms that play important roles in cell adhesion and signaling, which may promote cell proliferation, differentiation, survival, or migration.
Brok, J, Pritchard-Jones, K, Yap, L-W
core